US EditionRechallenging Immunotherapy Plus Anlotinib in Lung Cancer
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Rechallenging Immunotherapy Plus Anlotinib in Lung Cancer
In the relentless battle against advanced non-small cell lung cancer (NSCLC), a groundbreaking retrospective study has shed light on the promising potential of combining immune checkpoint inhibitors (ICIs) with anlotinib as a rechallenge therapy after prior immunotherapy failure. Conducted at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, this investigation provides crucial insights into managing NSCLC patients who la…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
